PRE-CLINICAL DEVELOPMENTDeeper molecular insights supporting accurate decision-making
The use of Next Generation Sequencing (NGS) technologies allows detecting even subtle effects of your compounds in cell lines and animal models.
Genomic analysis in the pre-clinical stage has the potential to:
- Identify new pathways involved in the disease - Suggest new therapeutic targets - Predict adverse drug effects
CLINICAL DEVELOPMENTThe power of genomics through your pipeline
DRUG REPURPOSINGHelping you find smarter ways
BIOMARKER IDENTIFICATION AND ANALYSISSee the difference
COMPANION DIAGNOSTICS AND KIT DEVELOPMENTAlways sharp on target
A unique tool in the industry, GeneSystems makes it possible to access all your data on a 24/7 basis, thus allowing you to monitor the entire analysis process in real time. It includes advanced annotation tools to assist in diagnosis and research, including links to the latest public and private databases.
Sistemas Genomicos’ quality has been accredited by a number of public bodies, including the CLIA certification from the Centers for Medicare and Medicaid Services (USA), that allows us to accept diagnostic samples from the United States.
We currently hold an ISO 9001 certificate for DNA sequencing, an ISO 13485 for the manufacturing of medical devices for in vitro diagnostics (sequencing kits for genetic testing) and an ISO 15189 for PGD/PGS analyses, among other accreditations and certifications.
We also participate in interlaboratory tests to ensure the highest technical competence in diagnostics, such as the EMQN for BRCA and NIPT testing.
Sistemas Genómicos was created in 1998 as one of the earliest firms to provide contract research DNA sequencing. After only two years of creation, we made history by participating in the first DNA sequencing of a plant organism, Arabidopsis thaliana. This milestone permitted us to invest in better large-scale DNA sequencing technologies.
In 2003, we opened our biomedical division specialising in the diagnosis and research of genetic diseases. In 2005, we absorbed IGEM – Institute of Medical and Molecular Genetics, specializing in medical genetics and prenatal diagnosis. Eager to innovate and invest in new technologies, we acquired in 2008 one of the earliest Next Generation Sequencing platforms available, being the first company in Europe with this kind of technology, and one of the pioneers worldwide in applying this new technology to diagnostics.
In 2013, we launched GeneSystems, unique platform that gives the user complete control of the data, from raw sequencing reads to advanced variant annotation and filtering, through an online tool.
In 2015, we achieved both the accreditation for the manufacturing of medical devices and CE marking for our diagnosis sequencing-based kits, which allows molecular laboratories to perform even highly complex diagnostic molecular tests with all the guarantees and technical validity required for human diagnostics.
Today, we are a contract research organisation specialising in molecular testing and data analysis, helping pharmaceutical companies, contract research organisations and biotechs from more than 40 countries to manage their biomedical samples.
Accreditations - Certifications
Identifying drug response biomarkers: Life projectProject website: http://www.proyectolife.es/
Drug response biomarkers facilitate a personalized approach for the treatment of different oncological diseases. Recent advances in tumor biology and genetics along with the development of drugs for very specific therapeutic targets are increasing treatment options for each type of tumor based on their genetic characteristics.
Exome sequencing is an approach that involves obtaining essential information to define biomarkers of treatment response and to develop new targets for therapeutic intervention.
The aim of Sistemas Genómicos' contribution in LIFE project was the identification of novel response biomarkers to first-line therapies in triple negative breast cancer. This specific subtype of breast cancer constitutes about 15% of all diagnosed breast tumors and presents the worst prognosis. Given the low response rate to treatment and the high relapse rate in this subgroup of patients, the clinically-innovative research of treatment response markers and new therapeutic targets is essential.